Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD31/PECAM-1 Antibody (TLD-3A12), DyLight 350, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NB10064796UV
Description
CD31/PECAM-1 Monoclonal specifically detects CD31/PECAM-1 in Human, Mouse, Rat, Rabbit samples. It is validated for Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen.Specifications
CD31/PECAM-1 | |
Monoclonal | |
DyLight 350 | |
adhesion molecule, CD31, CD31 antigen, CD31/EndoCAM, EndoCAM, FLJ34100, FLJ58394, GPIIA′, PECA1, PECAM-1, PECAM-1, CD31/EndoCAM, platelet endothelial cell adhesion molecule, platelet endothelial cell adhesion molecule-1, platelet/endothelial cell adhesion molecule | |
Mouse | |
82.5 kDa | |
0.25 mL | |
Angiogenesis, Cancer, Cellular Markers, Cytoskeleton Markers, Embryonic Stem Cell Markers, Endothelial Cell Markers, Extracellular Matrix, Hematopoietic Stem Cell Markers, Immunology, Mesenchymal Stem Cell Markers, Myeloid Cell Markers, Signal Transduction, Stem Cell Markers | |
5175 | |
Mouse, Rat | |
Purified |
Flow Cytometry, ELISA, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunohistochemistry (Frozen) | |
TLD-3A12 | |
Flow Cytometry, ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen | |
PECAM1 | |
This CD31/PECAM-1 Antibody (TLD-3A12) was developed against activated, Lewis rat derived microglial cells . | |
Protein G purified | |
RUO | |
Primary | |
Recognizes rat PECAM-1 (CD31), a 661 amino acid type 1 transmembrane protein expressed primarily on endothelial cells, platelets and leucocytes. | |
Store at 4C in the dark. | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction